The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.
Chronic immune response dysregulation in MDS pathogenesis
Open accessAbstract
Chronic innate immune signaling in hematopoietic cells is widely described in myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly via pattern recognition receptors, increases the risk of developing MDS. An inflammatory component to MDS has been reported for many years, but only recently has evidence supported a more direct role of chronic innate immune signaling and associated inflammatory pathways in the pathogenesis of MDS. Here we review recent findings and discuss relevant questions related to chronic immune response dysregulation in MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Human myelodysplastic syndrome (MDS) HSPCs have shown significant innate immune system dysregulation and resistance to the pro-proliferative effects of inflammation [69,80,81].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dysregulated inflammatory signaling has emerged as a key partner alongside oncogenic mutations in the development and/or progression of hematological malignancy (Barreyro et al., 2018; Pietras, 2017).”
From PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress (2021) · cites this paper as Barreyro et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation, often associated with increased IL-1 activity, is a common phenotype in individuals at risk for hematological malignancy, which can be related to several preexisting factors, including aging/tissue decline, genotoxin exposure, metabolic dysfunction, and/or autoimmune disease (Barreyro et al., 2018; Pietras, 2017).”
From PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress (2021) · cites this paper as Barreyro et al., 2018
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Pyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,288
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell
Osawa, M., Hanada, K., Hamada, H., & Nakauchi, H. (1996) · Science · doi:10.1126/science.273.5272.242 · Cited by 2,141
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis
Kaufmann, E., Sanz, J., Dunn, J. L., Khan, N., Mendonça, L. E., Pacis, A., Tzelepis, F., Pernet, E., Dumaine, A., Grenier, J.-C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.031 · Cited by 1,191
Dnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122
Cited by
Sorted by citations
Items 101–200 of 226
Bahmani, F., Shayanmanesh, M., Safari, M., Alaei, A., Pouriafar, Y., Rasti, Z., Zaker, F., Rostami, S., Damerchiloo, F., & Safa, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03793-z · Cited by 12
Mangaonkar, A. A., & Patnaik, M. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056175 · Cited by 11
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1819233 · Cited by 11
Bauer, M., Vaxevanis, C., Al‐Ali, H. K., Jaekel, N., Naumann, C. L. H., Schaffrath, J., Rau, A., Seliger, B., & Wickenhauser, C. (2021) · Cancers · doi:10.3390/cancers13020186 · Cited by 11
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Kapoor, S., Champion, G., Basu, A., Mariampillai, A., & Olnes, M. J. (2021) · Cancers · doi:10.3390/cancers13195026 · Cited by 11
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
Matsui, S., Ri, C., Bolanos, L. C., Choi, K., Shibamiya, A., Ishii, A., Takaishi, K., Oshima‐Hasegawa, N., Tsukamoto, S., Takeda, Y., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02245-3 · Cited by 10
Self-citationJavier, J. E., Hinge, A. S., Bartram, J., Xu, J., & Filippi, M. (2021) · Haematologica · doi:10.3324/haematol.2020.273292 · Cited by 10
Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia
Perna, F., Espinoza-Gutarra, M. R., Bombaci, G., Farag, S. S., & Schwartz, J. E. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_8 · Cited by 11
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
Comont, T., Treiner, E., & Vergez, F. (2021) · Diagnostics · doi:10.3390/diagnostics11111982 · Cited by 10
Přibyl, M., Hubáčková, S., Moudrá, A., Vančurová, M., Polackova, H., Stopka, T., Jonasova, A. T., Bokorová, R., Fuchs, O., Stritesky, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12768 · Cited by 10
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
Simoni, Y., & Chapuis, N. (2022) · Diagnostics · doi:10.3390/diagnostics12071659 · Cited by 9
Inflammatory signaling in the pathogenesis of acute myeloid leukemia
Baumann, A., & Ellegast, J. M. (2025) · HemaSphere · doi:10.1002/hem3.70188 · Cited by 9
Acquired and hereditary bone marrow failure: A mitochondrial perspective
Nasr, W., & Filippi, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048746 · Cited by 9
Muto, T., Walker, C. S., Agarwal, P., Vick, E. J., Sampson, A. M., Choi, K., Niederkorn, M., Ishikawa, C., Hueneman, K. M., Varney, M. E., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282349 · Cited by 9
Self-citationPellagatti, A., & Boultwood, J. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101055 · Cited by 10
EnvIRONmental Aspects in Myelodysplastic Syndrome
Petzer, V., Theurl, I., Weiß, G., & Wolf, D. G. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105202 · Cited by 10
Graf, J. R., Forster, S., Bruehl, F. K., Banz, Y., Hallal, M., Brodard, J., Bacher, U., Allam, R., Schürch, C. M., & Bonadies, N. (2021) · Cancers · doi:10.3390/cancers13225712 · Cited by 9
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma
DeStefano, C. B., Gibson, S. J., Sperling, A. S., Richardson, P. G. G., Ghobrial, I. M., & Mo, C. C. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.009 · Cited by 11
Moon, I., Kong, M. G., Ji, Y. S., Kim, S. H., Park, S. K., Suh, J., & Jang, M. (2022) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.2.145 · Cited by 9
Zeng, X., Wang, Y., Dai, M., Li, W., Huang, Q., Qin, L., Li, Y., Yan, Y., Xue, X., Yi, F., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05165-z · Cited by 8
Canonical Wnt: a safeguard and threat for erythropoiesis
Krimpenfort, R. A., & Nethe, M. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004845 · Cited by 11
Solimando, A. G., Melaccio, A., Vacca, A., & Ria, R. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.166 · Cited by 9
Aref, S., Khaled, N., Gilany, A. H. A., Ayed, M. B., Abouzeid, T., & Attia, D. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.10.2949 · Cited by 8
Apodaca, E., Demichelis‐Gómez, R., Rosas‐López, A., Mejía‐Domínguez, N. R., Galvan-López, I., Addorosio, M., Tracey, K. J., & Valdés‐Ferrer, S. I. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221125990 · Cited by 7
Microbiota Influences on Hematopoiesis and Blood Cancers: New Horizons?
Galloway-Peña, J., & Jobin, C. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0172 · Cited by 9
Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization
Vick, E. J., Hassan, A., Choi, K., Bennett, J. R., Muto, T., Clough, C. A., Culver‐Cochran, A. E., Hueneman, K. M., Bolanos, L. C., Wunderlich, M., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02695-3 · Cited by 7
Self-citationLyu, C., Liu, K., Jiang, Y., Wang, T., Wang, Y., & Xu, R. (2021) · Hematology · doi:10.1080/16078454.2021.1938429 · Cited by 7
Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis
de Matos, A. G., Magalhães, S. M. M., & Rauh, M. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_608 · Cited by 7
Wang, Y., Lin, C., Yao, C., Hsu, C., Tsai, C., Hou, H., Chou, W., & Tien, H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17837 · Cited by 7
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Tasis, A., Spyropoulos, T., & Mitroulis, I. (2025) · Cancers · doi:10.3390/cancers17050749 · Cited by 6
The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms
Parciante, E., Cumbo, C., Anelli, L., Zagaria, A., Redavid, I., Minervini, A., Conserva, M. R., Tota, G., Coccaro, N., Tarantini, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054860 · Cited by 6
Liang, Q., Zhao, J., Zhang, L., Gao, Z., Pan, H., Fang, L., & Shi, J. (2022) · Medicine · doi:10.1097/md.0000000000031427 · Cited by 6
O'Connor, T. E., Shaw, R. C., Madero‐Marroquin, R., & Roloff, G. W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1180439 · Cited by 6
Putnam, C., Kondeti, L., Kesler, M. B. A., & Varney, M. E. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0374 · Cited by 6
Khalilian, P., Eskandari, N., Sharifi, M. J., Soltani, M., & Nematollahi, P. (2024) · Advanced Biomedical Research · doi:10.4103/abr.abr_67_23 · Cited by 6
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
Thalambedu, N., Lal, B. M., Harbaugh, B., Alapat, D. V., Gaddam, M., Sanchez, C. G., Kumaran, M. S., & Varma, A. (2025) · Cancers · doi:10.3390/cancers17030508 · Cited by 5
IRAK signaling in cancers: mechanisms, targeting, and clinical implications
Vick, E. J., & Starczynowski, D. T. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2573646 · Cited by 5
Self-citationBoura-Theodorou, A., Psatha, K., Maniatsi, S., Kourti, A., Kaiafa, G. D., Aivaliotis, M., & Makedou, K. (2025) · Proteomes · doi:10.3390/proteomes13020021 · Cited by 5
de Sousa, J. C., Ito, M., Costa, M. B., Farias, I. R., Borges, D. D. P., de Oliveira, R. T., Fukutani, K. F., Thomé, C. H., Martinelli, C. M. D. S., Miyajima, F., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2608 · Cited by 5
Zhao, X.-C., Sun, X.-Y., Ju, B., Meng, F., & Zhao, H. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i11.1429 · Cited by 5
Moura, A. A., Bezerra, M. J. B., Martins, A. M. A., Borges, D. D. P., de Oliveira, R. T. G., de Oliveira, R. M., Farias, K. M., Viana, A. G. D. A., de Carvalho, G. G. C., Paier, C. R. K., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.833068 · Cited by 5
Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia
Brunner, A. M. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000749 · Cited by 5
Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding
Kida, J., & Chlon, T. M. (2024) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000854 · Cited by 4
Self-citationTLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells
Lawler, M. E., Romer-Seibert, J. S., Bowman, M. S., Mitra, R., Eischen, C. M., Bowman, R. L., & Meyer, S. E. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017018 · Cited by 4
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., & Wu, Y. (2025) · Biomolecules · doi:10.3390/biom15060761 · Cited by 5
Cavalcante, C. B. A., Chaves, A. C., de Oliveira, V. S., de Araújo, M. A. S., Silva, T. M., Goes, J. V. C., de Oliveira, R. T. G., Pinheiro, R. F., & Ribeiro, H. L. (2025) · Apmis · doi:10.1111/apm.70065 · Cited by 4
Recipient factors influencing red blood cell alloimmunization
Hendrickson, J. E. (2019) · ISBT Science Series · doi:10.1111/voxs.12485 · Cited by 4
High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms
Sampaio, L. R., Viana, M. D. A., de Oliveira, V. S., Ferreira, B. V., Melo, M. M. D. L., de Oliveira, R. T. G., Borges, D. D. P., Magalhãesa, S. M. M., & Pinheiro, R. F. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.05.002 · Cited by 4
Jachiet, V., Hadjadj, J., Zhao, L., Chasset, F., Fain, O., Fenaux, P., & MEKINIAN, A. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.02.023 · Cited by 5
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies
Chlon, T. M., & Patnaik, M. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.27091 · Cited by 4
Self-citationGut Microbiota Composition Correlates with Disease Severity in Myelodysplastic Syndrome
Riello, G. B. C., da Silva, P. M., Oliveira, F. A. D. S., de Oliveira, R. T. G., da Silva, F. E. R., França, I. G. D. F., Miyajima, F., Melo, V. M. M., Pinheiro, R. F., & Macêdo, D. S. (2024) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v18i2.15377 · Cited by 4
Lee, Y.-T., Wang, W., Kuo, C., Lee, M., Lu, Y., Hsiao, C., Hsu, Y., & Hung, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.568350 · Cited by 4
The role of innate immunity in MDS pathogenesis
Sallman, D. A., & List, A. F. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000217 · Cited by 4
Six-packed antibodies punch better
Rader, C. M., & Wiestner, A. U. (2019) · Haematologica · doi:10.3324/haematol.2019.224196 · Cited by 4
Weiss, D. J., & Sellon, R. K. (2022) · Schalm's Veterinary Hematology · doi:10.1002/9781119500537.ch67 · Cited by 4
The immunobiology of myelodysplastic neoplasms: a mini-review
Kannan, S., Vedia, R. A., & Molldrem, J. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419807 · Cited by 5
Li, X., Li, Q. Y., Xiang, X., Zhang, X., & Wu, Y. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156856 · Cited by 5
Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
Burke, S., Chowdhury, O., & Rouault‐Pierre, K. (2025) · HemaSphere · doi:10.1002/hem3.70103 · Cited by 4
Zhou, Y., Zhang, X., Yin, S., Yao, Y., Chen, T., Huang, L., & Liu, Z. (2025) · Inflammation Research · doi:10.1007/s00011-025-02038-z · Cited by 3
Wu, J., Liu, J., Chen, J., Yang, L., Li, F., Qin, T., Xu, Z., Liu, J., Zhou, J., Shi, L., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00664-1 · Cited by 3
Somatic mutations in aplastic anemia: Significance for classification, therapy, and outcome
Wood, H. J., & Marsh, J. C. W. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000212 · Cited by 3
Myelodysplastic Syndrome: A Real-World Experience from a Developing Country
Awidi, A., Alzubi, M., Odeh, N. W., Alrawabdeh, J. A., Zyoud, M. A., Hamadneh, Y. I., Bawaneh, H., Magableh, A., Al-Shorman, A., Al-Fararjeh, F., et al. (2022) · JCO Global Oncology · doi:10.1200/go.23.00281 · Cited by 3
A germline ETV6 mutation disrupts hematopoiesis via de novo creation of a nuclear export signal
McConville, M., Thomas, T., Beckner, R. L., Kroger, B. R., Valadez, C., Chook, Y. M., Chung, S. S., & Liszczak, G. (2025) · Science Advances · doi:10.1126/sciadv.adu4058 · Cited by 4
Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs
Feng, Y., Chen, C., Shao, A., Zhang, Q., Sun, L., Hu, H., & Zhang, T. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110963 · Cited by 2
Advances in the study of TIM3 in myelodysplastic syndrome
Guo, X., Yu, S., Tao, J., Wang, Y., Shao, Z., Fu, R., & Li, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1647401 · Cited by 2
Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes
Zhang, Z., Huang, N., Xv, F., Zhao, S., Guo, J., Zhao, Y., & Chang, C. (2022) · Current Oncology · doi:10.3390/curroncol29100545 · Cited by 3
Zhao, X.-C., Ju, B., Xiu, N.-N., Sun, X.-Y., & Meng, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339971 · Cited by 4
Fuchs, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00046-9 · Cited by 2
The immunoregulatory role of monocytes and thrombomodulin in myelodysplastic neoplasms
Janssen, L. L. G., van Leeuwen-Kerkhoff, N., Westers, T. M., de Gruijl, T. D., & van de Loosdrecht, A. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414102 · Cited by 2
New insights into PSAT1 as a therapeutic target for myelodysplastic syndrome (MDS)
Alatawi, S. M., & AlZamzami, W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309456 · Cited by 2
Xu, W., & Chang, C.-K. (2024) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2024.104041 · Cited by 2
Carlsten, M., Rossi, E. L. L., Jädersten, M., Tesi, B., Own, S. A., Sander, B., Deneberg, S., Ivinskiy, A., Sonnevi, K., Sjölund, H., et al. (2025) · HemaSphere · doi:10.1002/hem3.70160 · Cited by 2
Id1 promotes clonal hematopoiesis in mice with Tet2 loss of function
Singh, S., Gudmundsson, K. O., Sarkar, T., Jakubison, B. L., Morris, H. M., Burkett, S. S., Karim, B. O., Pauly, G. T., Sigano, D. M., Schneider, J. P., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr5867 · Cited by 4
Almosailleakh, M., Bentivegna, S., Narcisi, S., Benquet, S. J., Gillberg, L., Montano‐Almendras, C. P., Savickas, S., Schoof, E. M., Wegener, A., Luche, H., et al. (2023) · Genes · doi:10.3390/genes14101947 · Cited by 2
Acute Myeloid Leukemia Genomics: Impact on Care and Remaining Challenges
Eisfeld, A., & Mardis, E. R. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad171 · Cited by 2
Fueling clonal dominance through TRAFficking of NF-κB signaling
Ueda, K., Kumari, R., & Steidl, U. G. (2020) · Nature Immunology · doi:10.1038/s41590-020-0662-0 · Cited by 2
Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation
Wang, W., Zhang, X., Li, Y., Shen, J., Li, Y. F., Xing, W., Bai, J., Shi, J., & Zhou, Y. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10737-z · Cited by 1
Passos, P. R. C., Vieira, A. A., de Melo, R. P. M., FILHO, R. F. P., Sampaio, L. G., dos Santos, H. V. G., Sampaio, L. R., Goes, J. V. C., Magalhães, S. M. M., & Pinheiro, R. F. (2025) · Hematological Oncology · doi:10.1002/hon.70104 · Cited by 1
Huang, Y., Yi, P., Wang, Y., Wang, L., Cao, Y., Lu, J., Fang, K., Cheng, Y., & Miao, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565954 · Cited by 1
Induced pluripotent stem cell-based modelling of disease evolution in myeloid leukemia: MDS to AML
Boultwood, J. (2025) · Advances in Biological Regulation · doi:10.1016/j.jbior.2025.101119 · Cited by 1
Park, M., Choi, D.-H., Jang, J. H., Jung, C. W., Kim, H., & Kim, H.-Y. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197074 · Cited by 1
Мещерякова, Е. Ю., Krasnov, K. S., Odinokova, I. V., Lomovsky, A. I., Krestinina, O. V., Baburina, Y. L., Mikheeva, I. B., Mikhailova, G. Z., Сенотов, А. С., Nekhochina, P. S., et al. (2025) · Biomolecules · doi:10.3390/biom15121635 · Cited by 1
The role of macrophages and cytokines in the occurrence and development of MDS
Li, P. J., Li, S., Guan, D., Xu, W., Bian, J., Deng, J., Wang, H., & Ren, F. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02106-6 · Cited by 1
Wu, N., Liu, J., Lv, M., Mo, X., Sun, Y., Cheng, Y., Xu, L., Zhang, X.-H., Huang, X.-J., & Wang, Y. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110710 · Cited by 1
Inflammatory signatures in the spectrum of myeloid diseases
Ibbotson, A., Crouch, S., Ferrari, J., Young, T., Morgan, A. W., Gallì, A., Pozzi, S., Sarchi, M., Camilotto, V., Boldini, M., et al. (2026) · HemaSphere · doi:10.1002/hem3.70428 · Cited by 1
Recent Developments in Myelodysplastic Syndromes
Fuchs, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73936 · Cited by 1
Ubiquitination is not omnipresent in myeloid leukemia
Nayak, R. C., & Cancelas, J. A. (2019) · Haematologica · doi:10.3324/haematol.2019.224162 · Cited by 1
Wang, C., Yan, Y., Li, M., Zhao, Q., Perumal, G. B. P., & Gao, S. (2020) · Immunotherapy · doi:10.2217/imt-2020-0130 · Cited by 1
Wawrzycki, B., Jawniak, D., Pietrzak, A., Szumiło, J., & Krasowska, D. (2021) · Acta Haematologica Polonica · doi:10.5603/ahp.2021.0020 · Cited by 1
Kinoshita, S., Komatsu, H., Fujinami, H., Yoshida, T., Suzuki, T., Narita, T., Ito, A., Ri, M., Kusumoto, S., & Iida, S. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03453-2 · Cited by 1
Enigmatic missense mutations can cause disease via creation of de novo nuclear export signalsPreprint
McConville, B. M., Thomas, T., Beckner, R. L., Valadez, C., Chook, Y. M., Chung, S. S., & Liszczak, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.24.590854 · Cited by 1
Introductory Chapter: Progress in Myelodysplastic Syndrome Area
Fuchs, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84594
Miscellaneous Manifestations of Behçet Syndrome
Nowatzky, J., & Fresko, İ. (2019) · Springer eBooks · doi:10.1007/978-3-030-24131-5_10
Villaume, M. T., Ferrell, P. B., & Savona, M. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_4 · Cited by 1
Bauer, M., Vaxevanis, C., Al‐Ali, H. K., Jaekel, N., Naumann, C. L. H., Schaffrath, J., Rau, A., Seliger, B., & Wickenhauser, C. (2020) · Preprints.org · doi:10.20944/preprints202009.0280.v1
Recurrent hyperhemolytic transfusion reaction in myelodysplastic syndrome- A case based approach
Augustine, M., Murugesan, M., Nair, C. K., Raghavan, V., & Nayanar, S. K. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103073
Nimer, S. D., & Martín, G. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735593832.793562376
Süsgün, S., Baykara, O., Yücesan, E., Kuru, R. D., ÇAKMAK, B. A., Yabacı, A., Öngören, Ş., Deviren, A., & Argüden, Y. T. (2022) · Acta Medica Nicomedia · doi:10.53446/actamednicomedia.1096246
Chronic inflammation suppresses del(5q)-like MDS HSCs via p53Preprint
Muto, T., Walker, C. S., Choi, K., Niederkorn, M., Ishikawa, C., Varney, M. E., Hueneman, K. M., & Starczynowski, D. T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.22.497183
Self-citationAdkins, B. D., Mehta, A., Selesky, M., Vittitow, S. L., Smolkin, M. E., Ratcliffe, S. J., & Luckey, C. J. (2022) · Transfusion · doi:10.1111/trf.17155
Metadata
- Authors
- Barreyro, L., Chlon, T. M., & Starczynowski, D. T.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Barreyro, Laura
- Chlon, Timothy M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-10-11
- Volume
- 132
- Issue
- 15
- Pages
- 1553-1560
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC6182269
- OpenAlex
- W2885816375
- Cited by
- 226
- References
- 114
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 28 · 2023: 26 · 2022: 43 · 2021: 35 · 2020: 23 · 2019: 23 · 2018: 1
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Society of Hematology
- Leukemia and Lymphoma Society
- Cincinnati Children's Hospital Medical Center
- National Institutes of Health (1f32hl143993-01, RO1DK102759)
- National Heart, Lung, and Blood Institute (R35HL135787, F32 HL143993)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK102759, RO1DK102759, R01DK113639)
- National Institute of Environmental Health Sciences (T32ES007250)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- myelodysplastic syndrome, innate immune signaling, pattern recognition receptors, inflammation, hematopoietic cells, MDS pathogenesis
- MeSH terms
- Animals, Hematopoietic Stem Cells, Humans, Immunity, Innate, Inflammation, Myelodysplastic Syndromes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
